Gland Pharma (GLAND) Stock Overview
Engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for GLAND from our risk checks.
GLAND Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Gland Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,751.60 |
| 52 Week High | ₹2,131.00 |
| 52 Week Low | ₹1,277.80 |
| Beta | 0.41 |
| 1 Month Change | -7.74% |
| 3 Month Change | -7.43% |
| 1 Year Change | -3.40% |
| 3 Year Change | 1.44% |
| 5 Year Change | -21.86% |
| Change since IPO | -3.73% |
Recent News & Updates
Recent updates
Is Gland Pharma (NSE:GLAND) Using Too Much Debt?
Nov 08
Gland Pharma Limited's (NSE:GLAND) P/E Is On The Mark
Sep 15Here's What Analysts Are Forecasting For Gland Pharma Limited (NSE:GLAND) After Its First-Quarter Results
Aug 08Gland Pharma's (NSE:GLAND) Dividend Is Being Reduced To ₹18.00
Aug 05Is Gland Pharma (NSE:GLAND) Using Too Much Debt?
Jul 17Gland Pharma Limited Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next
May 23The Price Is Right For Gland Pharma Limited (NSE:GLAND)
Apr 09Results: Gland Pharma Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 06Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet
Jan 26
New Ampoule Line At Cenexi And Dr Reddy's Biologics Collaboration To Propel Revenue Growth And Enhance Earnings
New high-capacity ampoule line and leadership changes are expected to increase manufacturing capacity, customer service, and strategic execution, boosting revenue and margins.Gland Pharma Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next
Nov 07Gland Pharma Limited (NSE:GLAND) Shares Could Be 23% Above Their Intrinsic Value Estimate
Oct 26Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet
Oct 01Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)
Sep 05Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 09Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?
Jun 22Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts
May 25Is Gland Pharma (NSE:GLAND) A Risky Investment?
Mar 19Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion
Feb 16Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher
May 20Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 07Shareholder Returns
| GLAND | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.5% | -0.7% | -0.8% |
| 1Y | -3.4% | -2.8% | -2.0% |
Return vs Industry: GLAND matched the Indian Pharmaceuticals industry which returned -2.8% over the past year.
Return vs Market: GLAND underperformed the Indian Market which returned -2% over the past year.
Price Volatility
| GLAND volatility | |
|---|---|
| GLAND Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in IN Market | 8.5% |
| 10% least volatile stocks in IN Market | 3.0% |
Stable Share Price: GLAND has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: GLAND's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 4,351 | Shyamakant Giri | www.glandpharma.com |
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients.
Gland Pharma Limited Fundamentals Summary
| GLAND fundamental statistics | |
|---|---|
| Market cap | ₹288.59b |
| Earnings (TTM) | ₹7.90b |
| Revenue (TTM) | ₹58.01b |
Is GLAND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLAND income statement (TTM) | |
|---|---|
| Revenue | ₹58.01b |
| Cost of Revenue | ₹24.01b |
| Gross Profit | ₹34.00b |
| Other Expenses | ₹26.10b |
| Earnings | ₹7.90b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Jan 28, 2026
| Earnings per share (EPS) | 47.97 |
| Gross Margin | 58.61% |
| Net Profit Margin | 13.62% |
| Debt/Equity Ratio | 2.7% |
How did GLAND perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/06 20:41 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gland Pharma Limited is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashwin Mehta | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |